Vimarsana
Biggest News Aggregation in the World

Page 3 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement f - Vimarsana News

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement f

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)Takeda Will Make...

Takedas GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP - Vimarsana News

Takedas GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP

Takeda TSE4502NYSETAK today announced that the U.S. Food and Drug Administration FDA has approved GAMMAGARD LIQUID Immune Globulin Infusion Human 10 solution as an intravenous immunoglobulin IVIG therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy CIDP.

Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 29, 2024 at 11:11 am EST - Vimarsana News

Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 29, 2024 at 11:11 am EST

New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin Portfolio to Meet the Needs of People Living with CIDP Approval Supported by Phase 3...

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook - Vimarsana News

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023...

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases - Vimarsana News

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

Company to Feature 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology Hematology Presentations Include New Data from the Phase 3 and Continuation Trials Supporting...